Abstract Motor units are the fundamental elements responsible for muscle movement. They are formed by lower motor neurons and their muscle targets, synapsed via neuromuscular junctions (NMJs). The loss of NMJs in neurodegenerative disorders (such as amyotrophic lateral sclerosis or spinal muscle atrophy) or as a result of traumatic injuries affects millions of lives each year. Developing in vitro assays that closely recapitulate the physiology of neuromuscular tissues is crucial to understand the formation and maturation of NMJs, as well as to help unravel the mechanisms leading to their degeneration and repair. We present a microfluidic platform designed to coculture myoblast-derived muscle strips and motor neurons differentiated from mouse embryonic stem cells (ESCs) within a three-dimensional (3D) hydrogel. The device geometry mimics the spinal cord–limb physical separation by compartmentalizing the two cell types, which also facilitates the observation of 3D neurite outgrowth and remote muscle innervation. Moreover, the use of compliant pillars as anchors for muscle strips provides a quantitative functional readout of force generation. Finally, photosensitizing the ESC provides a pool of source cells that can be differentiated into optically excitable motor neurons, allowing for spatiodynamic, versatile, and noninvasive in vitro control of the motor units.

Keywords

Microfluidics

optogenetics

neuromuscular junctions

tissue engineering

INTRODUCTION Motor units, consisting of lower motor neurons (MNs) and the muscle fibers that they innervate via neuromuscular junctions (NMJs), are the fundamental elements responsible for producing virtually all motor functions, from locomotion to respiration or speech. Their failure is associated with highly incapacitating or lethal genetic disorders, such as amyotrophic lateral sclerosis (ALS), spinal muscle atrophy (SMA), or Duchenne muscular dystrophy (DMD) (1), or traumatic injuries. Serving as a model for synaptic function, motor units have been the object of previous pioneering work that led to the identification of neurotransmitters and their quantal release (2, 3). In vertebrates, NMJ function involves numerous specialized cell types, from astrocytes secreting supporting factors to Schwann cells providing electrical and chemical isolation (4, 5). Commonly used primitive animal models, such as aplysia, Caenorhabditis elegans, or Drosophila larva, provide important but limited insight into the physiology of vertebrate and mammalian NMJs due to fundamental differences in these models, such as the absence of synapse elimination and remodeling, the presence of glutamatergic MNs or inhibitory NMJs, and the absence of myelin sheath (6–8). On the other hand, mammalian in vivo models are complex and not amenable to systematic parameter tuning. Development of in vitro systems that mimic their in vivo counterparts and allow for de novo NMJ formation therefore remains a high priority. Traditional two-dimensional (2D) culture platforms, advantageous for their simplicity, typically consist of a layer of myotubes differentiated from myoblasts onto which MNs are uniformly plated (9–17). These 2D mixed culture systems, using various combinations of human, rodent, or chick cells, have been used for decades and have contributed greatly to our understanding of the fundamental physiology of NMJs; examples include acetylcholine receptor (AChR) clustering (9), the role of Schwann cells on NMJ formation (10), or the regulation of acetylcholinesterase activity (11). They have also proven to be efficient tools to investigate the functionality of healthy (12, 13) and dysfunctional (14) stem cell–derived MNs and have served to optimize in vitro neuron/muscle culture conditions (15–17). However, their simplicity can, at times, be outweighed by their limitations. The 2D nature of the system leads to a mismatch between the mechanical properties of the cells and the substrate that can impede muscle differentiation (18) or affect neurite outgrowth (19, 20) and preclude direct interaction between the extracellular matrix (ECM) and the resident neurons and muscle cells (21, 22). The mixed nature of the cultures makes it difficult to monitor individual cell types or axonal outgrowth and hinders the proper supply of tissue-specific factors or drugs. Moreover, the contraction generated by the muscle tissue can only be qualitatively assessed. Finally, these traditional platforms do not favor high throughput and limit scientists’ ability to automate cell handling and data acquisition. Over the years, progress has been made toward addressing some of these limitations associated with the traditional assays. Campenot chambers (23) have been used for compartmentalized 2D cocultures to study synapse elimination (24) or allow for enhanced visualization of axonal outgrowth (25). Microfluidic devices confer a higher throughput while increasing manipulability and control over culture conditions and have been proposed and applied to remotely innervate cardiac cells with autonomic neurons (26, 27) or skeletal muscle cells with MNs (28–31). Other systems enable culture in a 3D configuration in an attempt to increase the physiological relevance. They take the form of organotypic spinal cord slices in contact with myoblast-laden fibrin gels (32) or microdevices inspired by 3D muscle culture systems (33, 34), allowing the formation of 3D muscle bundles onto which MN-containing neurospheres were seeded (35). However, these configurations lacked clear physical separation between cell types. Finally, some platforms have used compliant substrates to quantitatively infer muscle contraction, whether by plating the cells on arrays of microneedles (36), flexible membranes (37), or silicon cantilevers (38, 39). This latter concept was the basis for a study that reported the formation of functional NMJ between MNs and muscle cells plated onto these cantilevers and the high-throughput and quantitative assessment of neuromuscular physiology and drug response (40). Here, we present an in vitro platform that is made more “physiologically relevant” by allowing simultaneous 3D coculture and compartmentalization of mouse embryonic stem cell (mESC)–derived MNs and skeletal muscle cells within an ECM. This platform capitalizes on microfluidic designs for 3D cell culture (41–43) and the use of passive force transducers for quantitative measurement of muscle contraction (44, 45) [reviewed in the study by Uzel et al. (46)]. The system enables the culture of functional differentiated MNs and myofibers, the observation of 3D axonal outgrowth with the hydrogel, and the formation of functional NMJs. To facilitate MN excitation and provide a means of rapid, spatially resolved and noninvasive MN activation, we use the optically excitable cation channel Channelrhodopsin-2 (ChR2). ChR2 and other opsins of the same family have proven to be valuable and versatile tools in neuroscience (47, 48) and have been widely used in in vivo models to stimulate NMJs (49–52). Here, we photosensitize an mESC line with an optimized ChR2 (ChR2H134R) and subsequently differentiate these cells into MNs to optically induce action potentials (APs) and interrogate the NMJ. This method, recently applied to ESCs overexpressing glia-derived neurotrophic factors (GDNFs) for enhanced survival (53) and even more recently to human induced pluripotent stem (iPS) cells (54), foreshadows how any pluripotent cell lines (a fortiori patient-derived iPS cells) can provide consistent optogenetically modified MNs. After characterizing the optogenetic targeting of the ESC and the optical excitability of the ChR2H134R-ESC–derived MNs, we demonstrate their ability to trigger the contraction of muscle cells first in a traditional dish assay, as well as in our new 3D compartmentalized microfluidic device.

DISCUSSION The combination of microfluidic and optogenetic technologies has enabled the development of a highly controllable and physiologically relevant in vitro model for motor units, with applications ranging from fundamental scientific studies to drug screening assays. Light stimulation of ChR-expressing ES-derived MNs provides great versatility over the excitation of the tissue by making it cell-specific and more spatiotemporally resolved than chemical stimulation. The PDMS-based microfluidic platform encompasses technologies that bring together essential aspects of neuromuscular tissue culture, namely, the 3D compartmentalized nature of the neuron-muscle coculture along with a functional force readout. The microfluidic chambers provide a 3D configuration similar to that of the native tissue, where one channel serves as a surrogate for the spinal cord, whereas the other one models the remotely innervated muscle tissue as found in the body wall or limbs. This culture system confers not only a softer mechanical substrate that 2D systems often lack but also the ability to investigate the role of the surrounding ECM. Compartmentalization further facilitates visualization of axonal outgrowth and innervation through a relevant matrix or the supply of cell-specific chemical cues and would allow for the manipulation of axons without interfering with other cell types. Finally, the integration of force sensors to the design offers a live, noninvasive, and quantitative assessment of muscle differentiation and contraction and synapse function. First, the ability to photosensitize nonaltered ESCs and differentiate them into optically excitable MNs raises the potential for more versatile ways of investigating disease models, such as SMA or ALS, by delivering ChR to the commercially available patient-derived iPS cells, already shown to be differentiable into functional MNs (62, 63). This is a process that could be combined with recent advances in transcriptional programming that drastically increase the yield and decrease the duration of MN differentiation from human ESC and mESC (64, 65). The demonstration of optically controlled NMJs in vitro will find application in diverse fields. For instance, much is yet to be understood regarding the process of NMJ maturation and remodeling, specifically how activity or exercise is responsible for plastic synaptic adaptation (24). The ability to selectively excite MNs or muscle cells [by selectively expressing ChR in one or the other or taking advantage of wavelength-specific opsin variants (66)] will greatly facilitate identifying the contributions of each synaptic partner in their anterograde and retrograde signaling (67–69). We also foresee applications in the fields of soft robotics or nanorobotics, defined as microfabricated motile substrates actuated by muscle cells recapitulating locomotive tasks (70–74). The use of optogenetic MNs will provide a level of spatiotemporal control capable of emulating the fine input command of the motor cortex. Overcoming the challenges of coculturing optogenetically modified MNs and skeletal muscle cells in a microfluidic device, featuring a compliant 3D matrix and in a spatially organized and compartmentalized fashion, all contributed to creating an NMJ microenvironment that brings together fundamental aspects of physiological neuromuscular tissues. The confinement by a microfluidic chamber did not impair myogenesis, and neither did the presence of the surrounding hydrogel. The spontaneous axonal outgrowth allowed for a remote innervation and emergence of light-excitable NMJs. Although the isotropic neurite outgrowth could be the result of a weak chemotactic gradient generated by the muscle-derived factors, another explanation is that the MNs are not mature enough to express the appropriate chemoattractant receptor or that the subtype of MNs thus differentiated is irresponsive to the factors secreted by the muscle cell (75–77). The ability to isolate the motor somata from the muscle cells is crucial for imaging the navigation of axons within a wide extracellular space and could prove useful in further understanding the process of nerve degeneration and repair in a functional context. Moreover, with some further engineering of the muscle consisting of fluorescently tagging the AChRs (78) or postsynaptic scaffolding proteins, such as Rapsyn (79), one could monitor the time course of synapse remodeling upon MN or muscle stimulation (69). This feature is also the first of its kind to allow for the supply of each cell type with its own medium in such a 3D environment in the form of two opposite gradients [as demonstrated with fluorescent tracers (fig. S8)]. This medium segregation could enhance neuromuscular tissue survival and NMJ maturation in vitro, which could be beneficial for long-term NMJ cultures (80). In addition, this asymmetry of chemokine supply can be used in a variety of applications, from testing the influence of cytokine gradients in the context of spinal cord development and axon pathfinding to the supply of cell-specific drugs. Although contact between motor neurites and muscle bundles was observed by day 4 of coculture in all tissues, only ~50% of the muscle constructs could be stimulated via neuronal excitation. This moderate success rate in generating functional light-excitable NMJs and incomplete innervation is likely attributable to poor accessibility of the myofibers to the incoming growth cone, because some were found within the muscle bundle. A potential solution to this problem could be to form multiple thinner muscle strips as described recently, which would provide more entry points to incoming axons (81, 82). Moreover, the resulting force that was 70% of the maximum force generated by total myofiber recruitment could find an extra explanation in the fact that tetanus could not be observed in muscle bundles stimulated by the MNs (whereas they were via direct electrical excitation). Although consistent with the existing studies conducted on NMJ formed in vitro with either C2C12 or primary myoblasts (15, 30, 35, 40), these systems could benefit from both recent myogenesis protocols from heterogeneous primary muscle cultures resulting in physiologic force generation (83), and genetically modified GDNF-expressing ESC-derived MNs leading to higher survival and firing rate (53). To further increase the physiological relevance of the system, other cell types could be added to the culture. This could be done either by taking advantage of, or even tuning, the heterogeneity of the differentiated cells within the neurospheres (the non-MN ChR2-expressing cells in fig. S7A are likely to be interneurons interacting via excitatory or inhibitory signals) or by complementing the surrounding matrix with supporting cells. For instance, Schwann cells, responsible for axon guidance, myelination, nerve repair (84), or NMJ formation and function (5, 10), could be added to the surrounding hydrogel. Doing so could also provide precious functional and quantitative insight in the myelination process along with demyelinating neuropathies, such as the Guillain-Barre syndrome (85) or Charcot-Marie-Tooth disease (86). The integration of compliant micropillars as anchoring points for the muscle bundles allows for a rapid, passive, and noninvasive assessment of muscle passive tension and active contraction. In a drug-screening assay, this contractile functional output provides a means of assessing the downstream and cumulative efficacy of a drug on motor unit recovery, a method used in the past in muscle bundle cultures (87) or in NMJ culture on cantilevers (40) and termed high-content screening. Ongoing work is focusing on increasing the throughput of the system to make this possible and would provide a new addition to the ever-growing list of organs on a chip (88).

MATERIALS AND METHODS Microfluidic device fabrication The mold fabrication followed a process similar to previously reported (41, 42). Briefly, designs were generated using AutoCAD (Autodesk), and the patterns were transferred to a Mylar transparency mask using high-resolution printing (FineLine Imaging). Silicon wafers were then fabricated by photolithography using an SU-8 photoresist (MicroChem). Unlike the top microfluidic part of the device that was casting from a negative mold, the master for the bottom pillar part was a positive version of it. All molds were surface-treated overnight before any PDMS (Ellsworth Adhesives) casting using (tridecafluoro-1,1,2,2-tetrahydrooctyl)-1-trichlorosilane (United Chemical Technologies). For the top microfluidic part, PDMS, mixed at 10:1 base/curing agent, was poured onto the silicon mold at a height of 5 mm, degassed in a desiccator, and cured at 80°C for at least 4 hours. Devices were then cut off the mold and trimmed to the appropriate size, and gel filling ports, vacuum port, and medium ports/reservoirs were formed with 1-, 2-, and 4-mm-diameter biopsy punches, respectively. For the bottom pillar part, a negative version of the mold was made with PDMS mixed at a 5:1 base/curing agent. It was then silanized overnight, and the same PDMS mixture was spun on top of the negative mold for 10 s at 500 rpm and 15 s at 1000 rpm, yielding membranes with thicknesses of ~100 μm. The membrane featuring the pillars was gently peeled off. Each pillar had a slight conical shape, reminiscent of the microfabrication process, with basal and tip diameters of 75 and 100 μm, respectively, and a height of 280 μm. The membrane pillar devices were then bonded to a 20-mm × 20-mm coverslip by plasma activation (Harrick Plasma) for rigidity purposes. The caps of the pillars consisted of 150-μm × 150-μm squares of 25-μm-thin PDMS (obtained by spin-coating it on a 10-cm petri dish for 30 s at 5000 rpm), manually positioned over the pillar, and glued with uncured PDMS, which resulted in a total height of 305 μm. Both top and bottom parts of the device were then cleaned by sonication in a bath of ethanol, followed by a sonicated bath of deionized (DI) water. They were then sterilized by a cycle of wet autoclaving, followed by dry autoclaving. The parts were aligned and assembled using a stereomicroscope under sterile conditions. After usage, the devices were cleaned by sonication in ethanol and then DI water, sterilized by autoclaving (a wet cycle followed by a dry cycle), and stored in a sterile container before further use. No devices were used more than 10 times. Cell culture and differentiation Source cells. mESC line HBG3 (Hb9-GFP), a gift from H. Wichterle, Columbia University, NY, was kept in culture on a feeder layer of mouse embryonic fibroblasts (CF-1 MEF Feeder Cells, Applied StemCell) plated on 0.1% gelatin–coated dishes in undifferentiated medium consisting of EmbryoMax ES Dulbecco’s modified Eagle’s medium (DMEM) (Millipore Chemicon), 15% ESC-qualified fetal bovine serum (Invitrogen), 1% nucleosides (Millipore Chemicon), 1% nonessential amino acids (Millipore Chemicon), 1% penicillin-streptomycin (Invitrogen), 1% l-glutamine (Invitrogen), 0.1 mM β-mercaptoethanol (Sigma), and 0.1% leukemia inhibitory factor (EMD). Mouse myoblasts C2C12 (89) [American Type Culture Collection (ATCC)] were cultured below 70% confluency in growth medium consisting of high-glucose DMEM (ATCC), 10% fetal bovine serum (Invitrogen), and 1% penicillin-streptomycin. All cells were kept in incubators at 37°C and 5% CO 2 . None of the cells were used beyond a passage number 20. Motor neurons. The MN differentiation protocol was adapted from published literature (55). Briefly, mESCs were collected from their feeder layer culture and plated at 2 × 106 cells in 10 ml in a 10-cm Nunc culture dish in differentiation medium, consisting of 1:1 Advanced DMEM/F-12 (Invitrogen)/Neurobasal (Invitrogen), 10% KnockOut Serum Replacement (Invitrogen), 1% penicillin-streptomycin (Invitrogen), 1% l-glutamine (Invitrogen), and 0.1 mM β-mercaptoethanol (Sigma). They were allowed to form EBs overnight. The next day, EBs in suspension were collected and transferred to low-adhesion culture dishes in 10 ml of differentiation; the cells that had attached to the Nunc dishes were discarded. On day 2, the medium was changed and supplemented with 1 μM RA (Sigma) and, on day 3, with 1 μM SAG (EMD). The cells remained in this medium for two more days. On day 5, the medium was replaced by differentiation medium supplemented with GDNF (10 ng ml−1) (R&D Systems) and CNTF (10 ng ml−1) (R&D Systems). EBs were used on day 7, either seeded in the microfluidic devices or dissociated and FACS-sorted to isolate Hb9GFP+/ChRtdTom+ MNs for plating on a glial feeder layer or muscle cell in 2D cultures. MN–glial cell coculture for electrophysiological recordings. Petri dishes (35 mm, BD Biosciences) were coated with a poly-d-lysine (PDL) (Sigma) coating solution at a concentration of 200 μg ml−1 and incubated at 37°C overnight. After PDL solution was washed with DI water, a laminin coating solution (Invitrogen) was used at a concentration of 10 μg ml−1 and incubated for at least 4 hours. The laminin coating solution was rinsed once before glial cells (Supplementary Materials) were plated at ~1 × 105 cells per dish and allowed to form a monolayer over at least 5 days in high-glucose DMEM (ATCC) containing 10% HS (Invitrogen) and 1% penicillin-streptomycin (Invitrogen). Dissociated MNs were then plated at 1 × 105 cells per dish, and the medium was switched to MN growth medium supplemented with GDNF at 10 ng ml−1, CNTF at 10 ng ml−1, 3-isobutyl-1-methylxanthine (IBMX) (Sigma) at 100 μM, and forskolin (Sigma) at 10 μM. Half of the medium was replaced every day until the cultures were used for electrophysiological recordings. MN–muscle cell coculture for NMJ in 2D. This procedure is a modified version of a previously published one (17). Similar to the glial cell culture, 35-mm petri dishes were coated with PDL (200 μg ml−1) and laminin (10 μg ml−1). C2C12 cells were plated at ~1 × 104 cells cm−2 and cultured in growth medium. The next day, the medium was switched to high-glucose DMEM supplemented with 2% HS and 1% penicillin-streptomycin. Two days later, the medium was supplemented with cytosine arabinoside (AraC) (Sigma-Aldrich) (1 μg ml−1) to eliminate the nonfused myoblast, and another 2 days later, early myotubes were trypsinized, replated at a 1:2 ratio on PDL- and laminin-coated 35-mm dishes, and cultured in medium consisting of 1:1 10% HS myogenic medium and neuronal differentiation medium supplemented with AraC (1 μg ml−1). On day 4 after myogenic induction, dissociated and purified Hb9GFP+/ChRtdTom+ MNs (see MN–glial cell coculture) were plated at 2 × 105 cells per dish. AraC was withdrawn from the medium and replaced with GDNF (5 ng ml−1), CNTF (5 ng ml−1), forskolin (5 μM), and IBMX (50 μM). In the subsequent days, half of the medium was replaced. Cell seeding and differentiation in the microfluidic device Cell seeding in the microfluidic device. All 3D cell cultures in the microfluidic devices were carried out in a collagen/Matrigel hydrogel in a 4:1 ratio. Rat tail type I collagen (Corning) was mixed on ice with 10× phosphate-buffered saline with phenol red (serving as a pH indicator), 0.5 N NaOH, and water for cell culture (Lonza) to yield a collagen concentration of 2 mg ml−1 at a pH of 7.4. Matrigel without growth factors (BD Biosciences) was thoroughly mixed with the collagen at 20% of the final gel mixture volume. The gel was then used within a few minutes following its preparation to avoid pre-polymerization. C2C12 cells were trypsinized, counted, and centrifuged for 5 min at 200 rcf. The pellet was then resuspended in the hydrogel at a final density of 2 × 106 cells ml−1. Shortly after resuspension, the hydrogel was injected into the rightmost channel of the microfluidic device that had been filled with medium before cell seeding. This later facilitated gel compaction because it allowed for the formation of a thin layer of medium that isolated the gel and the cells from the PDMS walls and reduced adhesion. The device was then placed in a humidified box and incubated at 37°C. To prevent cells from settling at the bottom of the device and ensuring a homogeneous distribution throughout the thickness of the channels, the devices were first placed upside down for 4 min and then rotated back to complete polymerization for the remaining 11 min. Growth medium was then supplied to the adjacent medium channel by forming a seal between a large-orifice pipette tip and the medium filling port and by pushing the medium into the channel. In the following days, the medium would seep through the dry channels to the left of the muscle chamber and fully wet all channels. The medium was replaced by removing approximately 50 μl of the old medium and replacing it with the same amount of fresh one. To prevent cross-flow that could wash off the gel, the medium was aspirated and supplied with a multichannel pipettor. The medium was changed every 24 hours. Muscle differentiation. After tissue ablation (see Supplementary Materials and Methods), the muscle bundles were supplied with myogenic medium consisting of 2% HS DMEM (Fig. 4). Three days after induction, the medium was replaced by 10% HS myogenic medium (more adequate for the metabolically active muscle strips) until device reassembly and MN seeding. Plasmid design and delivery DNA constructs were created using standard molecular biology techniques. Briefly, a ChR2[H134R]-tdTomato expression cassette was cloned into the Ai9 ROSA26 targeting vector and linearized for mESC knock-in (fig. S1A). Ai9 was a gift from H. Zeng (Addgene, plasmid no. 22799). For lentiviral infection of C2C12 cells, ChR2[H134R]-tdTomato was cloned downstream of an elongation factor 1α (EF1α) promoter in a lentiviral plasmid (fig. S5A). Mouse embryonic stem cell. The linearized ChR2[H134R]-tdTomato Rosa26 targeting vector (0.4 μg) was delivered to the mESC by nucleofection (Amaxa Nucleofector) for homologous recombination at the ROSA26 locus. Three days after plasmid delivery, a total of nine colonies were manually selected, on the basis of their ES-like morphologies and tdTomato expression, expanded, and tested for specific integration by Southern blotting. One clone displaying specific integration at the ROSA26 locus was selected for the rest of the study (fig. S1). C2C12. For lentivirus production, HEK293FT cells were seeded into a T225 flask at 40% confluency 24 hours before transfection. Cells were transfected with 10 μg of EF1α-ChR2[H134R]-tdTomato, 10 μg of pMD2.G, 15 μg of psPAX2, 100 μl of Lipofectamine 2000 (Life Technologies), and 200 μl of PLUS Reagent (Life Technologies). Six hours after transfection, fresh medium was applied. Three days after transfection, virus supernatant was harvested, filtered through a 0.45-μm polyvinylidene difluoride filter (Millipore), aliquoted, and stored at −80°C. Lentiviral packaging plasmids (psPAX2 and pMD2.G) were a gift from D. Trono (Addgene, plasmid nos. 12260 and 12259). C2C12 cells were incubated with viral supernatant for 24 hours. The cells were cultured for 3 days, then expanded for another 3 days, and sorted by FACS. Fifty percent of the brightest cells were collected of the 12% of positive cells to tdTomato. RNA extraction and reverse transcription quantitative polymerase chain reaction for gene expression analyses RNA was extracted using Izol (5 PRIME, 2302700) according to the manufacturer’s instructions. The extracted RNA (5 μg) was reverse-transcribed using M-MLV Reverse Transcriptase (Life Technologies, 28025-013) and random hexamers according to the manufacturer’s protocols. Quantitative polymerase chain reactions (PCRs) were performed with SYBR Green Master Mix (Roche). Relative mRNA levels were determined in triplicate for each transcript using the manufacturer’s software (Advanced Relative Quantification with Roche LightCycler 480 Software version 1.5) using Tubb5 transcript levels for normalization. The primers used for gene expression analyses are listed below. View this table: Southern blot analyses Genomic DNA was isolated from desired clones and digested with Bam H1-HF overnight. The digested DNA was run on a 1% agarose gel and transferred using the capillary transfer method. The clones were analyzed for targeting using an internal probe against ChR. This 809–base pair (bp) probe was amplified by PCR from the targeting vector using the following PCR primers: 5′-tcctggtccctgaggatcaa-3′ (forward) and 5′-gcggaacggagatcgaggtc-3′ (reverse). To check the correct targeting of the 5′ end, an 865-bp external probe was generated by digesting a vector containing the Rosa26 promoter (pROSA26-promoter; Addgene, no. 21710) with Sac I and Kpn 1. Immunostaining Cells were fixed with 4% paraformaldehyde for 20 min and then solubilized with 0.1% Triton X. After serum blocking, the cells were incubated at 4°C overnight with the primary antibody. The following day, the secondary antibody was administered for 2 hours at room temperature. Primary antibodies included anti-Oct4 (Abcam, 1:200) and anti-sarcomeric α-actinin antibody (Abcam, 1:400). Secondary antibodies, used at a 1:200 dilution, were goat anti-rabbit Texas Red (Invitrogen) and goat anti-mouse Alexa Fluor 488 (Invitrogen). NMJs were inhibited and stained in live or fixed cultures with Alexa Fluor 647–conjugated αBTX (Invitrogen) for 20 min in medium at a concentration of 5 μg ml−1. Counterstaining was performed with 4′,6-diamidino-2-phenylindole (Invitrogen, 1:1000). Electrophysiological assay For the patch clamp recordings, the FACS-sorted Hb9GFP+/ChRtdTom+ MNs were plated on primary mouse cortical glial cells (Supplementary Materials). The glial cells were plated at a density of 1 × 104 cells cm−2 on PDL-coated 35-mm petri dishes and allowed to reach confluency. Recordings were conducted on days 3, 10, and 16 after plating. The Hb9GFP+/ChRtdTom+ MNs were identified under a conventional inverted epifluorescence microscope (Axio Observer.A1, Zeiss) with a 20× objective lens [Plan-Neofluar; numerical aperture (NA), 0.4; Zeiss]. The formulation of the recording solutions was taken from past literature (64). The bath solution consisted of 145 mM NaCl, 5 mM KCl, 10 mM Hepes, 2 mM CaCl 2 , 10 mM glucose, and 2 mM MgCl 2 (pH 7.3 adjusted with NaOH, 325 mOsm adjusted with sucrose). The patch pipette solution contained 130 mM CH 3 KO 3 S, 10 mM CH 3 NaO 3 S, 1 mM CaCl 2 , 10 mM EGTA, 10 mM Hepes, 5 mM Mg–adenosine triphosphate, and 0.5 mM Na 2 –guanosine triphosphate (pH 7.3, 315 mOsm). The resistance of the electrodes was 4 to 8 megohms. Patch clamp experiments were performed using a Multiclamp 700B amplifier (Axon), and signals were digitized at 10 kHz with an Axon Digidata 1440A interface. Data were acquired with pClamp 10 software (Axon) and processed with MATLAB (MathWorks). For all voltage clamp experiments, the cells were held at a membrane potential of −60 mV. APs were recorded while holding the neurons to approximately −60 mV by injecting current with amplitudes no less than −300 pA. All recordings were conducted at room temperature. Optical and electrical stimulation All optical stimulations were performed using a SOLA light engine (Lumencor) excitation unit, with emission peaks of interest located at 470 and 540 to 550 nm. Blue and green lights were supplied through Zeiss filter sets #38 (BP 470/40) and #20 (BP 546/12), respectively. Unless otherwise stated, the entire field of view was illuminated. For the electrophysiological recordings, light was controlled by the Clampex software and applied through the 20× objective, yielding a maximum irradiance of 9 mW mm−2 as measured by a power meter (Newport) at the sample plane. The optical stimulations of the myofibers and MNs in adherent and microfluidic cultures were conducted through a 10× objective, yielding an irradiance of 7.6 mW mm−2 and controlled via an Arduino circuit board. Electrical stimulation was delivered via platinum electrodes positioned 3 mm away from each other across the neuromuscular tissue and controlled by an Arduino circuit delivering 9-V square inputs. Image acquisition and analysis Epifluorescence and confocal images were acquired on a Nikon Eclipse Ti-E inverted microscope and an Olympus FV-1000 confocal microscope, respectively. 3D reconstruction and analysis of confocal images were performed with the software Imaris (Bitplane). Automated tracking of the local deformation of the skeletal muscle cells and deflection of the pillars upon light excitation was carried out using the tracking software Tracker (http://physlets.org/tracker). The synchronization of deformation tracking and optical stimulation was carried out by plotting the average pixel intensity for every image over time and comparing the increase of intensity to the muscle or pillar deformation curve (fig. S3A). The blue bars correspond to periods of time when the light was on. Image analysis for muscle width and axon outgrowth was conducted in ImageJ (http://imagej.nih.gov/). Maximum neurite growth rate was defined as the speed of extension of the longest neurite with respect to the border of the EB on seeding day. Electrophysiology and FACS data were processed in MATLAB (MathWorks). Statistical analysis Statistical analysis was conducted in GraphPad Prism (GraphPad Software Inc.). Statistical significance analysis was done via t tests or one-way analysis of variance (ANOVA), and all tests resulting in a P value less than 0.05 were considered statistically significant.

SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/content/full/2/8/e1501429/DC1 Supplementary Materials and Methods fig. S1. DNA construct design, ESC colony morphology, DNA integration validation, and pluripotency characterization. fig. S2. Electrophysiological characterization of the ChR-HBG3-MN. fig. S3. Optogenetic activation of NMJs in adherent cocultures. fig. S4. Modes of tissue ablation. fig. S5. Photosensitization of the C2C12 myoblasts. fig. S6. Influence of the hydrogel on the force measured by the pillar. fig. S7. Motor neurite outgrowth in the microfluidic device. fig. S8. Opposite gradients as a mean to provide cell-specific medium. movie S1. Muscle contraction upon optical stimulation of ChR-HBG3-MN in adherent cultures. movie S2. ECM compaction and muscle bundle formation over the first 96 hours of the experiment. movie S3. 3D neurite outgrowth in the gel region bridging the neurosphere and the muscle strip. movie S4. Muscle bundle contraction upon light simulation of the ChR-HBG3-MN in the microfluidic device.

This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Acknowledgments: We thank H. Wichterle and T. Jessell for sharing the ES cell line HBG3 and to L. Wood for providing the glial feeder cells and insightful comments during manuscript preparation. We thank F. Zhang for providing resources and access to equipment for this project. We are also grateful to W. Li, K. Broderick, and T. Honegger for their guidance in microfabrication; N. Sanjana, J. Lefkowitz, and J. Pan for their training at electrophysiology and for making their scope available to us; and the Stice, Bashir, Saif, Gillette, Weiss, and Chen laboratories, together with D. Williams and J. Lichtman, for the insightful discussions. The help from M. Griffin and M. Jennings at the Koch Institute flow cytometry facility was greatly appreciated. We are grateful to S. Sakar and D. Neal for inspiring this study. We also thank N. Hammond and all the manuscript readers for their useful comments. Funding: S.G.M.U., V.S., and V.C. are grateful to the funding from the NSF Science and Technology Center for Emergent Behaviors of Integrated Cellular Systems (CBET-0939511). R.J.P. is supported by an NSF Graduate Research Fellowship under grant no. 1122374. C.J.R. is grateful for a Wellcome Trust MIT Postdoctoral Research Fellowship to carry out this research; this work was supported by the Wellcome Trust 093831/Z/10/Z. R.D.K. would like to acknowledge the following funding sources: National Research Foundation, Singapore-MIT Alliance for Research and Technology, and BioSystems and Micromechanics (BioSyM) IRG. Author contributions: S.G.M.U. designed the experiments and the microfluidic platform, created the cell line, conducted the experiments, analyzed the data, and prepared the manuscript. R.J.P. designed and fabricated the DNA construct, contributed to the cell line creation, and edited the manuscript. V.S. performed the molecular biology assays, contributed to the cell line creation, and edited the manuscript. T.M.P. conducted experiments and data analysis. C.J.R. built the laser ablation platform. V.C. performed the pillar stiffness measurement. L.A.B., P.T.C.S., and R.D.K. supervised the study and participated in the preparation of the manuscript. Competing interests: R.D.K. is a cofounder of AIM Biotech and has financial interest in this company. Data and materials availability: All data used to obtain the conclusions in this paper are present in the paper and/or the Supplementary Materials. Additional data related to this paper may be requested from the authors.